SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids

Biochemistry
O DelézayNouara Yahi

Abstract

Synthetic multibranched peptides derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120 inhibit HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms: competitive inhibition of HIV-1 binding to CD4-/GalCer+ colon cells and postbinding inhibition of HIV-1 fusion with CD4+ lymphocytes. In the present study, we have characterized the cellular binding sites for the V3 peptide SPC3, which possesses eight V3 consensus motifs GPGRAF radially branched on a neutral polyLys core matrix. These binding sites are glycosphingolipids that share a common structural determinant, i.e., a terminal galactose residue with a free hydroxyl group in position 4: GalCer/sulfatide on CD4-/GalCer+ colon cells; LacCer and its sialosyl derivatives GM3 and GD3 on CD4+ human lymphocytes. These data suggest that the V3 peptide binds to the GalCer/sulfatide receptor for HIV-1 gp120 on HT-29 cells and thus acts as a competitive inhibitor of virus binding to these CD4- cells, in full agreement with previously published virological data. In contrast, SPC3 does not bind to the CD4 receptor, in agreement with the data showing that the peptide inhibits HIV-1 infection of CD4+ cells by acting at a postattachment step. The binding of ...Continue Reading

References

Feb 28, 1991·Biochemical and Biophysical Research Communications·A HandaY Suzuki
Aug 1, 1990·Tissue Antigens·H YuasaA N Houghton
Jan 1, 1985·Annual Review of Biophysics and Biophysical Chemistry·T E Thompson, T W Tillack
Feb 1, 1984·Journal of Neurochemistry·K S Sundaram, M Lev
Mar 1, 1994·Journal of Neuroscience Research·T McAlarneyN Latov
Feb 1, 1996·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·Y MizrachiA Rubinstein
Mar 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S BaghdiguianJ Fantini

❮ Previous
Next ❯

Citations

Jan 24, 1998·Biochemical and Biophysical Research Communications·A PuriR Blumenthal
Jun 29, 2010·Glycoconjugate Journal·Amanda L HarrisonDonald R Branch
Jun 26, 1998·Progress in Lipid Research·I Ishizuka
Jun 6, 2000·Advanced Drug Delivery Reviews·I MartinR M Epand
May 11, 2011·Cold Spring Harbor Perspectives in Biology·Clifford A Lingwood
May 24, 2012·Journal of Lipid Research·Tadanobu Takahashi, Takashi Suzuki
Nov 25, 1998·Proceedings of the National Academy of Sciences of the United States of America·A PuriR Blumenthal
Jul 17, 1999·The Journal of Peptide Research : Official Journal of the American Peptide Society·M MoulardJ M Sabatier
Jun 2, 2015·Biological & Pharmaceutical Bulletin·Tadanobu Takahashi, Takashi Suzuki
Sep 29, 2009·Chemistry and Physics of Lipids·Clifford A LingwoodMurugesapillai Mylvaganam
May 26, 2015·European Journal of Medicinal Chemistry·Sandra García-GallegoM Ángeles Muñoz-Fernández
Oct 30, 2016·Biochimica Et Biophysica Acta. Biomembranes·Yoel A KlugYechiel Shai
Oct 19, 2016·International Journal of Molecular Sciences·Domenico RussoGiovanni D'Angelo
Jun 19, 2015·Clinical Microbiology Reviews·Laura Cooling
Jun 20, 2001·Nature Reviews. Molecular Cell Biology·J P Moore, M Stevenson
Nov 25, 2005·Bioscience Reports·Satinder S RawatAnu Puri
May 9, 2019·American Journal of Reproductive Immunology : AJRI·Charlene D YoungNongnuj Tanphaichitr

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.